Drug Trial Radar · NCT04976634
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
Last checked: Nov 20, 2026Latest source record: Apr 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
730
Planned (sponsor's estimate)
Start
Aug 18, 2021
Primary completion
Mar 22, 2027
Study completion Mar 22, 2027
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jul 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC),and esophageal squamous cell carcinoma (ESCC). There is no formal hypothesis testing in this study.
Conditions
- Neoplasm Malignant
Interventions
PembrolizumabDrug
Pembrolizumab 400 mg administered Q6W via IV infusion
BelzutifanDrug
Belzutifan 120 mg administered QD via oral tablet
LenvatinibDrug
Lenvantinib dose for HCC is 8 mg QD for body weight \<60 kg and 12 mg QD for body weight ≥ 60 kg administered via oral capsule. For all other tumors, the lenvatinib dose is 20 mg QD administered via oral capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Arm 1: Number of Participants Who Experience at Least One Dose-limiting Toxicity (DLT)Time frame: Up to approximately 21 days
- Arm 1: Number of Participants Who Experience at Least One Adverse Event (AE)Time frame: Up to approximately 67 months
- Arm 1: Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 67 months
- Confirmed Objective Response Rate (ORR) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 67 months
Locations
57 sites in 10 countries. Site status is shown where the registry gives one.
University of Arizona Cancer Center-University of Arizona Cancer Center - North Campus ( Site 5047)
Tucson, Arizona
City of Hope Comprehensive Cancer Center ( Site 5002)
Duarte, California
Cedars-Sinai Medical Center ( Site 5045)
Los Angeles, California
UCSF Medical Center at Mission Bay ( Site 5021)
San Francisco, California
Yale-New Haven Hospital-Yale Cancer Center ( Site 5013)
New Haven, Connecticut
Sibley Memorial Hospital ( Site 5051)
Washington D.C., District of Columbia
University of Florida College of Medicine ( Site 5015)
Gainesville, Florida
Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - GI and Immunology ( Site 5048)
Baltimore, Maryland
Brigitte Harris Cancer Pavilion ( Site 5055)
Detroit, Michigan
Memorial Sloan Kettering Cancer Center ( Site 5050)
New York, New York
Duke Cancer Institute ( Site 5026)
Durham, North Carolina
University of Texas MD Anderson Cancer Center-Gastrointestinal Medical Oncology ( Site 5049)
Houston, Texas
Inova Schar Cancer Institute ( Site 5039)
Fairfax, Virginia
Blue Ridge Cancer Care ( Site 5053)
Roanoke, Virginia
Northwest Medical Specialties, PLLC ( Site 5025)
Tacoma, Washington
University of Wisconsin Hospitals and Clinics ( Site 5037)
Madison, Wisconsin
Gosford Hospital-Oncology Trials ( Site 4004)
Gosford, New South Wales, Australia
Westmead Hospital-Department of Medical Oncology ( Site 4001)
Westmead, New South Wales, Australia
Northern Hospital-Department of Medical Oncology ( Site 4003)
Epping, Victoria, Australia
Cabrini Hospital - Malvern-Cabrini Institute ( Site 4000)
Malvern, Victoria, Australia
Université Catholique de Louvain-Namur - Centre Hospitalier -Oncology ( Site 1003)
Namur, Belgium
Antwerp University Hospital-Oncology ( Site 1002)
Edegem, Antwerpen, Belgium
Cliniques universitaires Saint-Luc-Medical Oncology ( Site 1001)
Brussels, Bruxelles-Capitale, Region de, Belgium
UZ Leuven ( Site 1000)
Leuven, Vlaams-Brabant, Belgium
AZ Delta vzw ( Site 1004)
Roeselare, West-Vlaanderen, Belgium
Centro Investigación del Cáncer James Lind ( Site 3107)
Temuco, Araucania, Chile
Clínica Puerto Montt ( Site 3110)
Port Montt, Los Lagos Region, Chile
FALP-UIDO ( Site 3102)
Santiago, Region M. de Santiago, Chile
Oncovida ( Site 3108)
Santiago, Region M. de Santiago, Chile
Bradfordhill-Clinical Area ( Site 3100)
Santiago, Region M. de Santiago, Chile
Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer ( Site 1103)
Rennes, Brittany Region, France
CHU Besançon-Medical oncology ( Site 1101)
Besançon, Doubs, France
CHU Brest Cavale Blanche ( Site 1107)
Brest, Finistere, France
Institut Regional du Cancer Montpellier ( Site 1106)
Montpellier, Herault, France
Hôpital Beaujon-Oncologie Digestive ( Site 1104)
Clichy, Île-de-France Region, France
Centre Hospitalier Universitaire de Grenoble-Medical Oncology ( Site 1105)
La Tronche, Isere, France
Sainte Catherine Institut du Cancer Avignon Provence ( Site 1108)
Avignon, Vaucluse, France
Rambam Health Care Campus-Oncology ( Site 1300)
Haifa, Israel
Hadassah Medical Center-Oncology ( Site 1303)
Jerusalem, Israel
Sheba Medical Center-ONCOLOGY ( Site 1302)
Ramat Gan, Israel
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.